The Next Wave of Neuromodulation

Neuromodulation used to be a quiet corner of medtech — a handful of chronic-pain and movement-disorder devices, slow-moving and predictable. That’s no longer true. A double-digit-growth market is now colliding with a patent landscape that shows, in granular detail, exactly where the next generation of competitive advantage is being built.

We reviewed the claims of 94 U.S. utility patents granted over the trailing 12 months, all directed at medtech neuromodulation, and layered that against two independent market research reports. Here’s what stands out.

The Market Is Accelerating

Sources: DelveInsight, “Neuromodulation Devices Market Insights, Competitive Landscape, and Market Forecast – 2034”; MarketsandMarkets, “US Neuromodulation Market (2025–2030)”

Three Structural Shifts Showing Up in the Patents

• Closed-loop is now the default, not the differentiator. The patent data matches the market — Medtronic’s BrainSense Adaptive DBS (FDA-cleared, Feb 2025) and Nevro’s HFX iQ / AdaptivAI are already commercial proof points.
• Energy delivery is going noninvasive. A large, tightly-fenced ultrasound patent family mirrors the market’s fastest-growing wearable/non-invasive segment.
• Software is now independently claimable IP. Mobile apps, NLP, digital twins, and even waveform “watermarking” are showing up as claim elements in their own right — not just supporting features.

A Large, Concentrating — But Not Locked-Down — Market

Two independent studies, one U.S.-focused and one global, agree on the broad picture: this is a large, accelerating, moderately concentrated market.

Figure 2 — Global market segmentation, 2025 (DelveInsight). Highlighted arc = leading sub-segment share.

Key Reads

• Device type: Spinal cord stimulators lead with 42% share; deep brain stimulators are the fastest-growing device category.
• Application: Pain management leads at 47% share; neurological disorders (Parkinson’s, tremor, epilepsy) are growing fastest.
• Invasive vs. noninvasive: Implantable systems still hold 94% share, but non-invasive/wearable is the fastest-growing pocket, gaining ground in migraine, depression, and rehabilitation.
• Site of care: Hospitals lead at 51% share, but specialty and ambulatory clinics are growing fastest as procedures shift outpatient.

Regional Landscape

• North America — 44% of global revenue, the largest region, backed by deep reimbursement infrastructure and a dense base of leading manufacturers.
• Asia-Pacific — the fastest-growing region, driven by rising disease burden and expanding neurosurgical infrastructure across China, Japan, India, South Korea, and Australia.
• Europe — large and technologically advanced, underpinned by CE Mark and national reimbursement frameworks.
• Rest of World — early-stage but emerging, aided by international training and technology-transfer partnerships.

What’s Driving Growth — and What’s Holding It Back

Growth drivers include rising chronic pain and failed back surgery syndrome, a growing Parkinson’s population (projected to reach 1.2M in the U.S. by 2030), commercial closed-loop/AI-enabled stimulation, expanding reimbursement, active M&A, and a broader physician push toward device-based, opioid-sparing pain therapy.

Restraints are equally clear: high upfront cost of implantable systems, uneven reimbursement across geographies, surgical risk (infection, lead migration, hardware complications), a shortage of trained implanting physicians, lengthy Class III regulatory pathways, and manufacturer consolidation that concentrates competitive and IP risk.

A Fast-Moving 18 Months: Recent M&A and Regulatory Milestones

The timeline below is effectively a ready-made diligence checklist for anyone tracking this space.

Who Actually Holds This IP?

Across the 94-patent set, Boston Scientific Corp leads with 16 patents — nearly 3x the next-closest owner, consistent with its dominant position in the spinal cord stimulation cluster and its long-running litigation history with Nevro.

GE Healthcare Technology’s 7 patents align with its known bioelectronic-medicine research program. Abbott and Spark Biomedical are tied at 6 each, with Spark’s position reflecting its focus on wearable auricular neurostimulation. Notably, the top 10 owners hold only 54% of the dataset — meaning 46% sits with a long tail of smaller and newer filers, a real signal of whitespace for new entrants.

Libbus and KenKnight are long-recognized names in cardiac/autonomic neuromodulation, consistent with the baroreflex and VNS activity attributed to LivaNova. Inventor concentration this tight is a useful diligence signal — a small set of named inventors often maps to a single core R&D team or lab.

Eight Technology Clusters, One Deep Dive

Grouping all 94 patents by primary technology focus produces eight clusters spanning implanted, wearable, and fully noninvasive neuromodulation. Cluster counts are additive — many patents span more than one.

Notable Patents at a Glance

Full 94-patent index available on request — the sample above spans all eight clusters.

Five Themes That Cut Across Every Cluster

• Closed-loop sensing is now the baseline, not the differentiator. Novelty is being pushed down into specifics — which signal, what triggers the change, how it’s computed.
• AI personalization meets an unsettled eligibility landscape. Following Recentive Analytics v. Fox Corp. (Fed. Cir., April 2025), generic “AI model” claims face real §101 exposure — USPTO’s rejection rate for AI/software claims in this examining group is estimated at roughly 77%, nearly double the 2022 rate.
• The invasive-to-noninvasive migration continues. Wearable devices are reaching indications once reserved for implants, with the ultrasound cluster the furthest point on that curve.
• Waveform engineering is its own patentable axis — largely independent of where in the body it’s delivered, and often under-valued when tied to a single product line.
• Software and data are now an independently claimable layer. Hardware-only claims risk being designed around; claims that also capture the data layer can outlive a hardware refresh cycle.

What This Means for IP Strategy

A few patterns are worth flagging for anyone building or evaluating a portfolio in this space:

• Numeric parameter ranges (frequency, pulse width, amplitude) remain the primary point of novelty — and their strength depends heavily on the supporting data behind them.
• Paired method and system/apparatus claims appear on nearly every patent, maximizing enforcement options.
• Means-plus-function language persists in hardware claims — directly relevant given Boston Scientific v. Nevro, where a 2020 Federal Circuit appeal turned partly on indefiniteness of terms like “paresthesia-free” and “means for generating.” The PTAB later invalidated 52 of 92 challenged claims across seven Boston Scientific patents.
• Continuation-family fencing is most visible in the ultrasound cluster, where multiple patents share near-identical specification language.

Company Snapshot

A quick reference on the scale of the established players versus the focused specialists active in this space.

Source: MarketsandMarkets, “US Neuromodulation Market (2025–2030),” Report Code BT 3571 US, published June 2026. Employee counts and ownership status are as reported in that study and should be reverified before use in client-facing material.

Where This Creates Opportunity

For firms and clients active in this space, the report points to several concrete engagement types worth raising proactively: freedom-to-operate and portfolio-gap studies for the crowded SCS space; §101 counseling for AI-personalization and closed-loop claims; continuation and claim-family strategy for platform-level mechanisms not yet fenced the way ultrasound is; litigation-readiness audits for means-plus-function-heavy portfolios; whitespace studies for the less-consolidated autonomic and emerging-indication clusters; and software/data-layer claim scope reviews for hardware-only patent holders.

The Bottom Line

The market backdrop is unambiguous — double-digit CAGR, a global market headed toward USD 15.85B by 2034, and an active M&A cycle already worth well over USD 750M in disclosed 2025 deal value. This is a growth market, not a mature one coasting on past approvals.

The core — spinal cord stimulation, established DBS — is consolidating around closed-loop, sensor-driven control, generating a steady stream of prosecution, licensing, and litigation-readiness work grounded in well-developed case law. The frontier — noninvasive ultrasound, autonomic targeting, AI-personalized control, and new indications — is still being written, and first-principles claim strategy here is where the deepest client relationships get built.

Ownership is concentrated, but not locked. Nearly half the dataset sits outside the top 10 owners. Real whitespace remains for new entrants and challengers willing to move first.